SWTX Key Statistics, Chart & Performance
The current stock price of SWTX is 46.99 USD. In the past month the price increased by 0.6%. In the past year, price increased by 27.79%.
SWTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SWTX. When comparing the yearly performance of all stocks, SWTX is one of the better performing stocks in the market, outperforming 81.49% of all stocks.
SWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SWTX. While SWTX has a great health rating, there are worries on its profitability.
SWTX Financial Highlights
Over the last trailing twelve months SWTX reported a non-GAAP Earnings per Share(EPS) of -3.41. The EPS increased by 33.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.25% | ||
| ROE | -60.84% | ||
| Debt/Equity | 0 |
SWTX Forecast & Estimates
11 analysts have analysed SWTX and the average price target is 53.33 USD. This implies a price increase of 13.5% is expected in the next year compared to the current price of 46.99.
For the next year, analysts expect an EPS growth of 19.4% and a revenue growth 71.54% for SWTX
SWTX Ownership
SWTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.78 | 380.43B | ||
| AMGN | AMGEN INC | 15.03 | 177.05B | ||
| GILD | GILEAD SCIENCES INC | 15 | 152.42B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.53 | 112.43B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.37 | 77.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 711.45 | 47.93B | ||
| INSM | INSMED INC | N/A | 34.56B | ||
| NTRA | NATERA INC | N/A | 32.36B | ||
| BIIB | BIOGEN INC | 9.99 | 24.54B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.73B | ||
| INCY | INCYTE CORP | 16.5 | 20.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.69 | 20.11B |
Related stock screener links
About SWTX
Company Profile
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 368 full-time employees. The company went IPO on 2019-09-13. The firm developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). The company is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Company Info
SPRINGWORKS THERAPEUTICS INC
100 Washington Blvd
Stamford CONNECTICUT 06902 US
CEO: Saqib Islam
Employees: 368
Phone: 12038839490
SPRINGWORKS THERAPEUTICS INC / SWTX FAQ
Can you describe the business of SPRINGWORKS THERAPEUTICS INC?
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 368 full-time employees. The company went IPO on 2019-09-13. The firm developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). The company is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
What is the stock price of SPRINGWORKS THERAPEUTICS INC today?
The current stock price of SWTX is 46.99 USD. The price increased by 0.02% in the last trading session.
What is the dividend status of SPRINGWORKS THERAPEUTICS INC?
SWTX does not pay a dividend.
What is the ChartMill rating of SPRINGWORKS THERAPEUTICS INC stock?
SWTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SPRINGWORKS THERAPEUTICS INC?
SPRINGWORKS THERAPEUTICS INC (SWTX) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for SWTX stock?
The Revenue of SPRINGWORKS THERAPEUTICS INC (SWTX) is expected to grow by 71.54% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.